Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Receivables (2016 - 2026)

Sunshine Biopharma filings provide 10 years of Receivables readings, the most recent being $3.5 million for Q4 2025.

  • On a quarterly basis, Receivables fell 10.56% to $3.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.5 million, a 10.56% decrease, with the full-year FY2025 number at $3.5 million, down 10.56% from a year prior.
  • Receivables hit $3.5 million in Q4 2025 for Sunshine Biopharma, down from $4.2 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $4.2 million in Q3 2025 to a low of $22.0 in Q3 2022.
  • Median Receivables over the past 5 years was $2.3 million (2023), compared with a mean of $2.2 million.
  • Biggest five-year swings in Receivables: tumbled 98.05% in 2022 and later soared 9245895.45% in 2023.
  • Sunshine Biopharma's Receivables stood at $7798.0 in 2021, then surged by 24421.07% to $1.9 million in 2022, then soared by 33.48% to $2.6 million in 2023, then surged by 51.56% to $3.9 million in 2024, then dropped by 10.56% to $3.5 million in 2025.
  • The last three reported values for Receivables were $3.5 million (Q4 2025), $4.2 million (Q3 2025), and $3.6 million (Q2 2025) per Business Quant data.